Titre du document / Document title

Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen

Auteur(s) / Author(s)

SCHAEFFER Anthony J. ⁽¹⁾ ; WU Shu-Chen ⁽²⁾ ; TENNENBERG Alan M. ⁽³⁾ ; KAHN James B. ⁽²⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Northwestern University Medical School, Chicago, Illinois, ETATS-UNIS
⁽²⁾ Ortho-McNeil Pharmaceutical, Inc, Bridgewater, New Jersey, ETATS-UNIS
⁽³⁾ Raritan and Tibotec Therapeutics, Bridgewater, New Jersey, ETATS-UNIS

Résumé / Abstract

Purpose: We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or ciprofloxacin. Materials and Methods: Subset analysis was done using a randomized, multicenter, double-blind, active control trial of 500 mg levofloxacin daily for 28 days vs 500 mg ciprofloxacin twice daily in 28 days in men with chronic bacterial prostatitis. Results: Of the 377 men in the intent to treat population, including 197 treated with levofloxacin and 180 treated with ciprofloxacin, 35 on levofloxacin and 37 on ciprofloxacin with baseline PSA greater than 4 ng/ml were included in this analysis. Excluded from analysis were 2 levofloxacin treated patients with extremely high PSA at baseline (62 and 103 ng/ml, respectively). Mean baseline PSA ± SD in the patients analyzed was 8.33 ± 4.46 ng/ml, which decreased to 5.36 ± 3.82 ng/ml after therapy. There was no significant difference in the mean change in PSA between the levofloxacin and ciprofloxacin groups. Approximately 42% of patients with increased baseline PSA had a post-therapy PSA of 4 ng/ml or less. Of patients who were microbiologically evaluable and had normalized PSA after therapy levofloxacin eradicated the pathogen in 90.9% (10 of 11). However, of patients in whom post-therapy PSA remained increased the microbiological eradication rate was 69.2% (9 of 13). Similarly 93.3% of the ciprofloxacin group (14 of 15 patients) with normalized post-therapy PSA experienced microbiological eradication compared with 61.5% (8 of 13) with continued increased PSA after therapy. Conclusions: Approximately 20% of patients diagnosed with chronic bacterial prostatitis had increased PSA. A significant decrease in PSA was observed in these patients after treatment with levofloxacin or ciprofloxacin. An association was observed between bacterial persistence and the likelihood that PSA would return to normal.

Revue / Journal Title

The Journal of urology   ISSN 0022-5347   CODEN JOURAA 

Source / Source

2005, vol. 174, n^o1, pp. 161-164 [4 page(s) (article)] (16 ref.)

Langue / Language

Anglais

Editeur / Publisher

Lippincott Williams & Wilkins, Hagerstown, MD, ETATS-UNIS  (1917) (Revue)

Mots-clés anglais / English Keywords

Quinolone derivatives ; Fluoroquinolone derivatives ; Urinary system disease ; Male genital diseases ; Prostate disease ; Infection ; Nephrology ; Antibacterial agent ; Urology ; Ofloxacin ; Prostate specific antigen ; Tumoral marker ; Serum ; Ciprofloxacin ; Levofloxacin ; Prostatitis ; Bacteria ; Bacteriosis ; Chronic ; Treatment ;

Mots-clés français / French Keywords

Quinolone dérivé ; Fluoroquinolone dérivé ; Appareil urinaire pathologie ; Appareil génital mâle pathologie ; Prostate pathologie ; Infection ; Néphrologie ; Antibactérien ; Urologie ; Ofloxacine ; Antigène spécifique prostate ; Marqueur tumoral ; Sérum ; Ciprofloxacine ; Lévofloxacine ; Prostatite ; Bactérie ; Bactériose ; Chronique ; Traitement ;

Mots-clés espagnols / Spanish Keywords

Quinolone derivado ; Fluoroquinolone derivado ; Aparato urinario patología ; Aparato genital macho patología ; Prostata patología ; Infección ; Nefrología ; Antibacteriano ; Urología ; Ofloxacino ; Antigeno específico prostata ; Marcador tumoral ; Suero ; Ciprofloxacino ; Levofloxacino ; Prostatitis ; Bacteria ; Bacteriosis ; Crónico ; Tratamiento ;

Mots-clés d'auteur / Author Keywords

prostate ; prostatitis ; ofloxacin ; ciprofloxacin ; prostate-specific antigen ;

Localisation / Location

INIST-CNRS, Cote INIST : 2081, 35400013860797.0360